This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Kozloff, Mark
| Item Type | Name |
|
Concept
|
Maximum Tolerated Dose
|
|
Academic Article
|
Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.
|
|
Academic Article
|
Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer.
|
|
Academic Article
|
An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer.
|
|
Academic Article
|
Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.
|
|
Academic Article
|
Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours.
|
|
Academic Article
|
A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.
|
|
Academic Article
|
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.
|
|
Academic Article
|
Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.
|
|
Academic Article
|
A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies.
|
|
Academic Article
|
Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing.
|